Defining the Ideal Patient with Hepatocellular Carcinoma for Second-Line Treatment

Table 2

Subgroup analysis of ramucirumab, regorafenib, and cabozantinib compared to placebo in HCC.

	HR	95% CI	value	I^2 (%)	value	Model
Age ≥65 years	0.75	0.64–0.88	<0.001	0	0.79	Fixed
Age <65 years	0.80	0.69–0.93	<0–001	9	0.35
Male	0.76	0.68–0.85	<0.001	27	0.25	Fixed
Female	0.79	0.60–1.05	0.10	0	0.56
ECOG: 0	0.70	0.60–0.80	<0.001	0	0.57	Fixed
ECOG: 1	0.88	0.75–1.03	0.11	0	0.11
Alpha-fetoprotein						Fixed
<400 ng/ml	0.85	0.73–1.00	0.05	68	0.05
≥400 ng/ml	0.70	0.69–0.85	<0.001	0	0.96
Macrovascular invasion						Fixed
Yes	0.75	0.62–0.91	<0.001	0	0.66
No	0.75	0.66–0.86	<0.001	20	0.29
Extrahepatic metastases						Fixed
Yes	0.70	0.62–0.80	<0.001	0	0.44
No	1.02	0.82–1.27	0.86	0	0.70
Virus						Fixed
HBV	0.71	0.60–0.84	<0.001	0	0.52
HCV	0.89	0.72–1.12	<0.32	0	0.67

HR: hazard ratio; CI: confidence interval.